NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.  Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development. C$86.8 million (US$61.1 million) in cash and cash equivalents […]